These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 738119

  • 1. Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation.
    Bennett DH.
    Chest; 1978 Dec; 74(6):624-8. PubMed ID: 738119
    [Abstract] [Full Text] [Related]

  • 2. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.
    Kerr CR, Prystowsky EN, Smith WM, Cook L, Gallagher JJ.
    Circulation; 1982 May; 65(5):869-78. PubMed ID: 6804107
    [Abstract] [Full Text] [Related]

  • 3. Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.
    Spurrell RA, Thorburn CW, Camm J, Sowton E, Deuchar DC.
    Br Heart J; 1975 Aug; 37(8):861-7. PubMed ID: 53057
    [Abstract] [Full Text] [Related]

  • 4. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
    Deano DA, Wu D, Mautner RK, Sherman RH, Ehsani AI, Rosen KM.
    Chest; 1977 May; 71(5):597-606. PubMed ID: 856558
    [Abstract] [Full Text] [Related]

  • 5. Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome.
    Fujimura O, Klein GJ, Sharma AD, Yee R, Szabo T.
    J Am Coll Cardiol; 1989 Apr; 13(5):1133-7. PubMed ID: 2926064
    [Abstract] [Full Text] [Related]

  • 6. Treatment of arrhythmias in the Wolff-Parkinson-White syndrome.
    Forester D.
    Chest; 1979 Jun; 75(6):745. PubMed ID: 436537
    [No Abstract] [Full Text] [Related]

  • 7. The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias.
    Camm J, Ward D, Spurrell RA.
    Br J Clin Pharmacol; 1979 Nov; 8(5):441-9. PubMed ID: 508548
    [Abstract] [Full Text] [Related]

  • 8. [Electrophysiological action of disopyramide].
    Grosu AA, Malakhov VI, Smetnev AS.
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1982 Nov; 5(2):51-5. PubMed ID: 7138657
    [Abstract] [Full Text] [Related]

  • 9. Clinical studies of Norpace (Part X).
    Dreifus LS.
    Angiology; 1975 Jan; 26(1 Pt 2):148. PubMed ID: 46728
    [No Abstract] [Full Text] [Related]

  • 10. Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome.
    Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, Kamakura S, Matsuhisa M, Shimomura K.
    Eur Heart J; 1992 Feb; 13(2):261-8. PubMed ID: 1555626
    [Abstract] [Full Text] [Related]

  • 11. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.
    Gulamhusein S, Ko P, Carruthers SG, Klein GJ.
    Circulation; 1982 Feb; 65(2):348-54. PubMed ID: 7053894
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of intravenous disopyramide in the termination of supraventricular arrhythmias.
    Luoma PV, Kujala PA, Juustila HJ, Takkunen JT.
    J Clin Pharmacol; 1978 Feb; 18(5-6):293-301. PubMed ID: 641217
    [No Abstract] [Full Text] [Related]

  • 13. Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: technique, application, and efficacy in severely symptomatic preexcitation patients.
    Bauernfeind RA, Swiryn SP, Strasberg B, Palileo E, Scagliotti D, Rosen KM.
    Am Heart J; 1982 Jun; 103(6):941-9. PubMed ID: 7081034
    [Abstract] [Full Text] [Related]

  • 14. Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation.
    Chimienti M, Moizi M, Salerno JA, Klersy C, Guasti L, Previtali M, Marangoni E, Montemartini C, Bobba P.
    Eur Heart J; 1987 Mar; 8(3):282-90. PubMed ID: 3107987
    [Abstract] [Full Text] [Related]

  • 15. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G, Lefkos N, Efthymiadis AP, Styliadis IG, Tsapas G.
    Acta Cardiol; 1995 Mar; 50(2):125-34. PubMed ID: 7610735
    [Abstract] [Full Text] [Related]

  • 16. Magnesium reversal of digoxin-facilitated ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome.
    Merrill JJ, DeWeese G, Wharton JM.
    Am J Med; 1994 Jul; 97(1):25-8. PubMed ID: 8030653
    [Abstract] [Full Text] [Related]

  • 17. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome.
    Morady F, DiCarlo LA, Baerman JM, De Buitleir M.
    Pacing Clin Electrophysiol; 1987 May; 10(3 Pt 1):492-6. PubMed ID: 2439997
    [Abstract] [Full Text] [Related]

  • 18. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome.
    McGovern B, Garan H, Ruskin JN.
    Ann Intern Med; 1986 Jun; 104(6):791-4. PubMed ID: 3706931
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of isoproterenol during atrial fibrillation in evaluation of asymptomatic Wolff-Parkinson-White pattern.
    Szabo TS, Klein GJ, Sharma AD, Yee R, Milstein S.
    Am J Cardiol; 1989 Jan 15; 63(3):187-92. PubMed ID: 2909998
    [Abstract] [Full Text] [Related]

  • 20. Flecainide in the Wolff-Parkinson-White syndrome.
    Crozier I.
    Am J Cardiol; 1992 Aug 20; 70(5):26A-32A. PubMed ID: 1509995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.